MedTrace Logo

Recall by Genotype: Neuropeptide Stimulation

NCT05901467 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-03-06

Study results available
· View outcomes & findings →

Summary

The objective of this protocol is to assess response to kisspeptin and gonadotropin-releasing hormone (GnRH) stimulation testing as well as the baseline patterns of luteinizing hormone (LH) secretion in individuals who carry variants in genes related to infertility.

Conditions

  • Reproductive Disorder

Interventions

DRUG

kisspeptin 112-121

One IV bolus of kisspeptin 112-121

DRUG

GnRH

One IV bolus of gonadotropin-releasing hormone

Sponsors & Collaborators

  • Stephanie B. Seminara, MD

    lead OTHER

Principal Investigators

  • Stephanie B Seminara, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-20
Primary Completion
2024-05-29
Completion
2024-05-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05901467 on ClinicalTrials.gov